Therapy News and Research

RSS

Auxilium reports net revenues of $66.7 million for third quarter 2011

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced financial results and operational highlights for the quarter ended September 30, 2011.

31 Oct 2011

Pacira's third quarter total revenues decrease to $4.0 million

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2011 and provided an update on the U.S. Food and Drug Administration's (FDA) approval of EXPAREL and the commercial strategy to support the product launch.

31 Oct 2011

Astex to present data on direct acting antiviral agents against HCV at 62nd AASLD meeting

Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics, announced that it will present data on its novel, first-in-class direct acting antiviral agents (DAA) against Hepatitis C Virus (HCV) at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

31 Oct 2011

FDA approves Pacira's EXPAREL for postsurgical pain management

Pacira Pharmaceuticals, Inc. announces that the U.S. Food and Drug Administration (FDA) has approved EXPAREL 1.3% for administration into the surgical site to produce postsurgical analgesia.

31 Oct 2011

Fierce Vaccines highlights Inovio's VGX-3100 as one of 10 Promising Therapeutic Vaccines

Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that VGX-3100, its investigational SynCon vaccine for treating cervical dysplasia and cancer caused by human papillomavirus, was highlighted by Fierce Vaccines as one of 10 Promising Therapeutic Vaccines.

31 Oct 2011

HAL Allergy initiates PURETHAL Mites PHASE II study

HAL Allergy B.V. today announced that it has included the first patient in its PHASE II dose range finding study.

31 Oct 2011

Mayo Clinic, Oxford BioMedica collaborate to develop gene therapy for glaucoma

Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that it has entered into a research and development collaboration with Mayo Clinic, Rochester (USA) to develop a novel gene therapy for the treatment of chronic glaucoma.

31 Oct 2011

Neutralization approach appears to prevent proliferative vitreoretinopathy

Proliferative vitreoretinopathy (PVR), or the formation of scar tissue within the eye, is a serious, sight-threatening complication in patients recovering surgical repair of retinal detachment. A new study conducted by investigators at the Schepens Eye Research Institute, the Department of Ophthalmology at Harvard Medical School, and the Massachusetts Eye and Ear Infirmary in Boston, published in the December issue of the American Journal of Pathology, suggests that a cocktail containing reagents to neutralize a relatively small subset of vitreal growth factors and cytokines may be an effective treatment.

31 Oct 2011

Ovarian cancer patients with many folate receptors benefit from new therapy

A new strategy that takes advantage of ovarian cancer's reliance on folate appears to give relapse patients extra months of life with few side effects, researchers say.

29 Oct 2011

Glitazone treatment does not cause side effects in patients with metastatic thyroid cancer

Repeated radio-ablation therapy with iodine-131 to treat metastatic thyroid cancer can be less effective than the initial round of treatment due to de-differentiation of the cancer cells as the disease progresses, making them less sensitive to I-131.

29 Oct 2011

'Heroes of Hope Race for Brain Tumor Research' event to be held on Nov. 6

Veronica Cappalonga, 28, knows a lot about living with cancer. Diagnosed at age 6 with leukemia and at 22 with a malignant brain tumor, the Los Angeles (Mar Vista area) resident will walk in the Nov. 6 Heroes of Hope Race for Brain Tumor Research - not only to help fundraise, but also to show that survivors can fight these diseases with dignity.

29 Oct 2011

Twelve students participate in Hartford Doctoral Fellows Program in Geriatric Social Work

Twelve outstanding students have been chosen as the newest participants in the Hartford Doctoral Fellows Program in Geriatric Social Work. The program is funded by the John A. Hartford Foundation, administered by The Gerontological Society of America, and directed by James Lubben, DSW, MPH.

29 Oct 2011

VUMC doctors to begin statin drug screening for rare genetic variation

Vanderbilt University Medical Center doctors announced today they will begin screening patients who take commonly prescribed statin drugs for a rare genetic variation that can increase risks for side effects from these drugs such as muscle aches, kidney damage and even death.

29 Oct 2011

Researchers uncover biochemical signals that trigger generation of new lung alveoli

Researchers at Weill Cornell Medical College say they have taken an important step forward in their quest to "turn on" lung regeneration -- an advance that could effectively treat millions of people suffering from respiratory disorders.

29 Oct 2011

Research focuses on JQ1 molecule that tricks NUT midline carcinoma cancer cells

NUT midline carcinoma (NMC) is a cancer without a cure, and one that affects all age groups. NMC is a rapid-growth disease with an average survival time of four and a half months after diagnosis, making the development of clinical trials for potential therapies or cures for this cancer difficult, to say the least.

29 Oct 2011

ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide in a pediatric sarcoma model.

29 Oct 2011

NYUCN to study 'Test and Linkage to Care Among Injecting Drug Users Kenya'

New York University College of Nursing (NYUCN) received a five-year, $4,161,665.00 grant from the National Institute of Health's National Institute on Drug Abuse (NIH/NIDA) to research "Test and Linkage to Care Among Injecting Drug Users (TLC_IDU) Kenya."

29 Oct 2011

More than 50,000 patients at high risk of SCA have been prescribed ZOLL's LifeVest

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that more than 50,000 patients at high risk of sudden cardiac arrest (SCA) have been prescribed the LifeVest Wearable Defibrillator.

29 Oct 2011

FDA approves Medtronic's LGS IDE for clinical trial to treat Type 1 diabetes

In our continued commitment to develop an artificial pancreas, Medtronic, Inc. today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) to conduct a pivotal in-home clinical trial protocol for the ASPIRE study of the MiniMed Paradigm System featuring Low Glucose Suspend (LGS) automation.

From Medtronic 29 Oct 2011